FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to method for predicting the likelihood of developing Alzheimer's disease (BA), including measuring human plasma enzyme activity of leukocyte elastase (LE) and functional activity α1-proteinase inhibitor (α1-PI) and the definition of the likelihood of developing Alzheimer's disease.
EFFECT: invention provides predictions for probability of asthma in patients with mild cognitive decline of the amnestic type (ISS).
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IDENTIFYING A GROUP OF PEOPLE WITH AN INCREASED RISK OF DEVELOPING ALZHEIMER'S DISEASE | 2021 |
|
RU2781612C1 |
| DIAGNOSTIC TECHNIQUE FOR ASTHENIC SYNDROME IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2709105C1 |
| METHOD OF ESTIMATION OF PATIENT'S MENTAL CONDITION WITH ENDOGENIC MENTAL DISORDERS AT THEIR CLINICAL EXAMINATION AND METHOD OF COMPLEX EVALUATION OF THE STATE OF THE IMMUNE SYSTEM OF SUCH PATIENTS | 2016 |
|
RU2648745C1 |
| METHOD FOR PREDICTION OF FUNCTIONAL RECOVERY OF PATIENTS WITH ISCHEMIC STROKE | 2018 |
|
RU2694541C1 |
| METHOD OF DETERMINING THE NECESSITY OF USING PSYCHO PHARMACOTHERAPY AMONG THE PATIENTS WITH DISORDERS OF AUTIST SPECTRUM AT THE MOMENT OF THEIR EXAMINATION | 2017 |
|
RU2643760C1 |
| ACTIVE INGREDIENT OF MEDICINAL AGENT, MEDICINAL AGENT, PHARMACEUTICAL CONPOSITION AND METHOD OF DEMENT SYNDROME TREATMENT | 2007 |
|
RU2327480C1 |
| USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
| LACTOFERRIN, USED IN DIAGNOSING OR PREDICTING ALZHEIMER'S DISEASE OR DIAGNOSING PARKINSON'S DISEASE | 2016 |
|
RU2745602C2 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE, VASCULAR AND MIXED DEMENTIA | 2015 |
|
RU2578188C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF MODERATE COGNITIVE DISORDERS | 2015 |
|
RU2588314C1 |
